Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life.
Our lead product candidate is an inhaled galectin-3 modulator, GB0139, currently in a Phase 2b study for the treatment of idiopathic pulmonary fibrosis. Our pipeline also includes GB1211, a selective oral galectin-3 inhibitor that we are developing for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that we plan to develop for the treatment of myelofibrosis. We plan to further expand the development of GB211 into other indications, including cancer .
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Management will be available for 1x1 meetings throughout the day. There is no presentation/webcast associated with this event.
Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter.